Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
i-LIVER: Imdusiran in Chronic Hepatitis B
NCT06154278Phase 2Recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Conjugated siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of imdusiran in Chronic Hepatitis B (CHB), sponsored by University of Maryland, Baltimore. Started Jul 2024; status: recruiting.
02
Drugs
imdusiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06154278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06154278.